Figure 5.
Overall survival stratified by (a) chromosome 21 status (Chr.21 loss versus No chr.21 loss) and (b) Loss of any chromosome among chromosome 1, 2, 6, 10, 13, 17, or 21 (Loss versus No loss) in 94 chRCC patients combined from Swiss and the Cancer Genome Atlas Kidney Chromophobe (TCGA-KICH) cohorts.